FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Samuel Bouchillon

Research Profile

Procedures

Chemicals & Drugs

Physiology

Living Beings

Disorders

Geographic Areas

Europe
Asia

Co-author Network

Publications

TOP 3
Karen O'Dwyer; Donghui Qin; Magdalena Zalacain; Kelly M Aubart; Samuel K Bouchillon; Meredith Hackel; Sarah Hightower; Daryl Hoban; Deborah Butler
Comparative Analysis of the Antibacterial Activity of a Novel Peptide Deformylase Inhibitor, GSK1322322.
Sibylle H Lob; Robert E Badal; Samuel K Bouchillon; Meredith A Hackel; Stephen P Hawser; Daryl J Hoban
Epidemiology and Susceptibility of Gram-Negative Appendicitis Pathogens: SMART 2008-2010.
Stephen P Hawser; Daryl J Hoban; Robert E Badal; Douglas J Biedenbach; Samuel K Bouchillon; Rafael Cantón; David L Paterson
Monitoring the global in vitro activity of ertapenem against Escherichia coli from intra-abdominal infections: SMART 2002-2010.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Samuel Bouchillon (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Karen O'Dwyer; Donghui Qin; Magdalena Zalacain; Kelly M Aubart; Samuel K Bouchillon; Meredith Hackel; Sarah Hightower; Daryl Hoban; Deborah Butler
Comparative Analysis of the Antibacterial Activity of a Novel Peptide Deformylase Inhibitor, GSK1322322.
Antimicrobial agents and chemotherapy 2013;57(5):2333-42.
2013: Sibylle H Lob; Robert E Badal; Samuel K Bouchillon; Meredith A Hackel; Stephen P Hawser; Daryl J Hoban
Epidemiology and Susceptibility of Gram-Negative Appendicitis Pathogens: SMART 2008-2010.
Surgical infections 2013;14(2):203-8.
2013: Stephen P Hawser; Daryl J Hoban; Robert E Badal; Douglas J Biedenbach; Samuel K Bouchillon; Rafael Cantón; David L Paterson
Monitoring the global in vitro activity of ertapenem against Escherichia coli from intra-abdominal infections: SMART 2002-2010.
International journal of antimicrobial agents 2013;41(3):224-8.
2012: Daryl J Hoban; Christine Lascols; Lindsay E Nicolle; Robert Badal; Samuel K Bouchillon; Meredith Hackel; Stephen Hawser
Antimicrobial susceptibility of Enterobacteriaceae, including molecular characterization of extended-spectrum beta-lactamase-producing species, in urinary tract isolates from hospitalized patients in North America and Europe: results from the SMART study 2009-2010.
Diagnostic microbiology and infectious disease 2012;74(1):62-7.
2012: Stephen P Hawser; Samuel K Bouchillon; Minjun Chen; Meredith Hackel; Eui-Chong Kim
Trending 7 years of in vitro activity of tigecycline and comparators against Gram-positive and Gram-negative pathogens from the Asia-Pacific region: Tigecycline Evaluation Surveillance Trial (TEST) 2004-2010.
International journal of antimicrobial agents 2012;39(6):490-5.
2012: S P Hawser; D Hoban; S Lob; Samuel K Bouchillon; R Badal
Susceptibility of global intra-abdominal Enterobacteriaceae isolates to tigecycline (TEST 2007-2010).
The Journal of infection 2012;64(6):620-2.
2012: Christine Lascols; Steven H Marshall; Robert E Badal; Samuel K Bouchillon; Meredith Hackel; Stephen P Hawser; Daryl J Hoban; Andrea Hujer; Robert A Bonomo
Using nucleic acid microarrays to perform molecular epidemiology and detect novel β-lactamases: a snapshot of extended-spectrum β-lactamases throughout the world.
Journal of clinical microbiology 2012;50(5):1632-9.
2012: S P Hawser; D J Hoban; C Lascols; R E Badal; Samuel K Bouchillon; M Hackel; Rafael Cantón
Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extended-spectrum β-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008-2009).
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2012;18(3):253-9.
2012: Stephen P Hawser; Daryl J Hoban; Christine A Lascols; Robert E Badal; Samuel K Bouchillon; Meredith A Hackel; Maria V Villegas; Flavia Rossi
Low frequency of ertapenem-resistant intra-abdominal isolates of Escherichia coli from Latin America: susceptibility, ESBL-occurrence, and molecular characterisation (SMART 2008-2009).
Journal of chemotherapy (Florence, Italy) 2012;24(1):6-11.
2012: Samuel K Bouchillon; Robert Badal; Daryl J Hoban; Stephen Hawser
Fluoroquinolone resistance among gram-negative urinary tract pathogens: global smart program results, 2009-2010.
The open microbiology journal 2012;6():74-8.
2011: S P Hawser; R E Badal; Samuel K Bouchillon; D J Hoban
Trending eight years of in vitro activity of ertapenem and comparators against Escherichia coli from intra-abdominal infections in North America--SMART 2002-2009.
Journal of chemotherapy (Florence, Italy) 2011;23(5):266-72.
2011: Christine Lascols; Steven H Marshall; Robert Badal; Samuel K Bouchillon; Meredith Hackel; Daryl Hoban; Andrea Hujer; Robert A Bonomo
Increasing prevalence and dissemination of NDM-1 metallo-β-lactamase in India: data from the SMART study (2009).
The Journal of antimicrobial chemotherapy 2011;66(9):1992-7.
2011: Daryl J Hoban; Lindsay E Nicolle; Samuel K Bouchillon; Stephen Hawser; Robert Badal
Antimicrobial susceptibility of global inpatient urinary tract isolates of Escherichia coli: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program: 2009-2010.
Diagnostic microbiology and infectious disease 2011;70(4):507-11.
2011: Yen-Hsu Chen; Po-Ren Hsueh; Robert E Badal; Stephen P Hawser; Daryl J Hoban; Samuel K Bouchillon; Yuxing Ni; David L Paterson
Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria.
The Journal of infection 2011;62(4):280-91.
2011: Stephen P Hawser; Samuel K Bouchillon; Daryl J Hoban; Michael Dowzicky; Tim Babinchak
Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004-2009.
International journal of antimicrobial agents 2011;37(3):219-24.
2011: S Hawser; Daryl J Hoban; Samuel K Bouchillon; R Badal; Y Carmeli; P Hawkey
Antimicrobial susceptibility of intra-abdominal gram-negative bacilli from Europe: SMART Europe 2008.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2011;30(2):173-9.
2010: Po-Ren Hsueh; Robert E Badal; Stephen P Hawser; Daryl J Hoban; Samuel K Bouchillon; Yuxing Ni; David L Paterson
Epidemiology and antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2008 results from SMART (Study for Monitoring Antimicrobial Resistance Trends).
International journal of antimicrobial agents 2010;36(5):408-14.
2010: Stephen P Hawser; Robert E Badal; Samuel K Bouchillon; Daryl J Hoban; Po-Ren Hsueh
Comparison of CLSI 2009, CLSI 2010 and EUCAST cephalosporin clinical breakpoints in recent clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca from the SMART Global Surveillance Study.
International journal of antimicrobial agents 2010;36(3):293-4.
2010: Stephen P Hawser; Robert E Badal; Samuel K Bouchillon; Daryl J Hoban
Antibiotic susceptibility of intra-abdominal infection isolates from Indian hospitals during 2008.
Journal of medical microbiology 2010;59(Pt 9):1050-4.
2010: Stephen P Hawser; Samuel K Bouchillon; Daryl J Hoban; Robert E Badal
Epidemiologic trends, occurrence of extended-spectrum beta-lactamase production, and performance of ertapenem and comparators in patients with intra-abdominal infections: analysis of global trend data from 2002-2007 from the SMART study.
Surgical infections 2010;11(4):371-8.
2010: Daryl J Hoban; Samuel K Bouchillon; Stephen P Hawser; Robert E Badal; Vincent J Labombardi; Joseph DiPersio
Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).
Antimicrobial agents and chemotherapy 2010;54(7):3031-4.
2010: Stephen P Hawser; Samuel K Bouchillon; Daryl J Hoban; Robert E Badal; Rafael Cantón; Fernando Baquero
Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrobial Resistance Trends (SMART).
Antimicrobial agents and chemotherapy 2010;54(7):3043-6.
2010: Daryl J Hoban; Samuel K Bouchillon; Stephen P Hawser; Robert E Badal
Trends in the frequency of multiple drug-resistant Enterobacteriaceae and their susceptibility to ertapenem, imipenem, and other antimicrobial agents: data from the Study for Monitoring Antimicrobial Resistance Trends 2002 to 2007.
Diagnostic microbiology and infectious disease 2010;66(1):78-86.
2009: Stephen P Hawser; Samuel K Bouchillon; Daryl J Hoban; Robert E Badal
In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli from patients with intra-abdominal infections worldwide from 2005-2007: results from the SMART study.
International journal of antimicrobial agents 2009;34(6):585-8.
2009: Stephen P Hawser; Samuel K Bouchillon; Daryl J Hoban; Meredith Hackel; Jack L Johnson; Robert E Badal
Klebsiellapneumoniae isolates possessing KPC beta-lactamase in Israel, Puerto Rico, Colombia and Greece.
International journal of antimicrobial agents 2009;34(4):384-5.
2009: Stephen P Hawser; Samuel K Bouchillon; Daryl J Hoban; Robert E Badal; Po-Ren Hsueh; David L Paterson
Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.
Antimicrobial agents and chemotherapy 2009;53(8):3280-4.
2009: Samuel K Bouchillon; Jonathan R Iredell; Timothy Barkham; Kyungwon Lee; Michael J Dowzicky
Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST).
International journal of antimicrobial agents 2009;33(2):130-6.
2007: Daryl J Hoban; Samuel K Bouchillon; Michael J Dowzicky
Antimicrobial susceptibility of extended-spectrum beta-lactamase producers and multidrug-resistant Acinetobacter baumannii throughout the United States and comparative in vitro activity of tigecycline, a new glycylcycline antimicrobial.
Diagnostic microbiology and infectious disease 2007;57(4):423-8.
2005: Daryl J Hoban; Samuel K Bouchillon; Brian M Johnson; Jack L Johnson; Michael J Dowzicky
In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004).
Diagnostic microbiology and infectious disease 2005;52(3):215-27.
2005: Samuel K Bouchillon; Daryl J Hoban; Brian M Johnson; Jack L Johnson; Andre Hsiung; Michael J Dowzicky
In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).
Diagnostic microbiology and infectious disease 2005;52(3):173-9.
2005: Samuel K Bouchillon; Jack L Johnson; Daryl J Hoban; Tim M Stevens; Brian M Johnson
Impact of carbon dioxide on the susceptibility of key respiratory tract pathogens to telithromycin and azithromycin.
The Journal of antimicrobial chemotherapy 2005;56(1):224-7.
2005: Samuel K Bouchillon; Daryl J Hoban; Brian M Johnson; Tim M Stevens; Michael J Dowzicky; David H Wu; Patricia A Bradford
In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002.
Diagnostic microbiology and infectious disease 2005;51(4):291-5.
2004: Samuel K Bouchillon; Brian M Johnson; Daryl J Hoban; Jack L Johnson; Michael J Dowzicky; D H Wu; Melissa A Visalli; Patricia A Bradford
Determining incidence of extended spectrum beta-lactamase producing Enterobacteriaceae, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in 38 centres from 17 countries: the PEARLS study 2001-2002.
International journal of antimicrobial agents 2004;24(2):119-24.
2004: Samuel K Bouchillon; Daryl J Hoban; Jack L Johnson; Brian M Johnson; DL Butler; KA Saunders; Linda A Miller; James Poupard
In vitro activity of gemifloxacin and contemporary oral antimicrobial agents against 27247 Gram-positive and Gram-negative aerobic isolates: a global surveillance study.
International journal of antimicrobial agents 2004;23(2):181-96.
2003: Daryl J Hoban; Samuel K Bouchillon; Jack L Johnson; GG Zhanel; DL Butler; KA Saunders; Linda A Miller; James Poupard
Comparative in vitro potency of amoxycillin-clavulanic acid and four oral agents against recent North American clinical isolates from a global surveillance study.
International journal of antimicrobial agents 2003;21(5):425-33.
2003: Daryl J Hoban; Samuel K Bouchillon; Jack L Johnson; GG Zhanel; DL Butler; KA Saunders; Linda A Miller; James Poupard
Comparative in vitro surveillance of amoxicillin-clavulanic acid and four oral comparators against 21232 clinical isolates from europe.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2003;22(4):261-7.
2001: MR Turnak; SI Bandak; Samuel K Bouchillon; BS Allen; Daryl J Hoban
Antimicrobial susceptibilities of clinical isolates of Haemophilus influenzae and Moraxella catarrhalis collected during 1999-2000 from 13 countries.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2001;7(12):671-7.
2001: Daryl J Hoban; Samuel K Bouchillon; Jack L Johnson; GG Zhanel; DL Butler; Linda A Miller; James Poupard
Comparative in vitro potency of gemifloxacin and fluoroquinolones against recent European clinical isolates from a global surveillance study.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2001;20(11):814-9.
2001: Daryl J Hoban; Samuel K Bouchillon; Jack L Johnson; GG Zhanel; DL Butler; Linda A Miller; James Poupard
Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study.
Diagnostic microbiology and infectious disease 2001;40(1-2):51-7.
2001: SI Bandak; MR Turnak; BS Allen; LD Bolzon; DA Preston; Samuel K Bouchillon; Daryl J Hoban
Antibiotic susceptibilities among recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis from fifteen countries.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2001;20(1):55-60.
2000: Daryl J Hoban; Samuel K Bouchillon; J A Karlowsky; Jack L Johnson; DL Butler; Linda A Miller; James Poupard
A comparative In vitro surveillance study of gemifloxacin activities against 2,632 recent Streptococcus pneumoniae isolates from across Europe, North America, and South America. The Gemifloxacin Surveillance Study Research Group.
Antimicrobial agents and chemotherapy 2000;44(11):3008-11.